WO2021184673A1 - Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof - Google Patents

Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof Download PDF

Info

Publication number
WO2021184673A1
WO2021184673A1 PCT/CN2020/109645 CN2020109645W WO2021184673A1 WO 2021184673 A1 WO2021184673 A1 WO 2021184673A1 CN 2020109645 W CN2020109645 W CN 2020109645W WO 2021184673 A1 WO2021184673 A1 WO 2021184673A1
Authority
WO
WIPO (PCT)
Prior art keywords
car
cells
cell
seq
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/109645
Other languages
English (en)
French (fr)
Inventor
Yihong Yao
Yanfeng Li
Yutian WEI
Shigui Zhu
Xin Yao
Jiaqi Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellular Biomedicine Group HK Ltd
Original Assignee
Cellular Biomedicine Group HK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Biomedicine Group HK Ltd filed Critical Cellular Biomedicine Group HK Ltd
Priority to CA3169235A priority Critical patent/CA3169235A1/en
Priority to JP2022506548A priority patent/JP7624967B2/ja
Priority to US17/911,502 priority patent/US20230104705A1/en
Priority to UAA202203670A priority patent/UA129998C2/uk
Priority to PL21772208.1T priority patent/PL3989986T3/pl
Priority to EP21772208.1A priority patent/EP3989986B1/en
Priority to PCT/US2021/022779 priority patent/WO2021188681A1/en
Priority to DK21772208.1T priority patent/DK3989986T3/da
Priority to JP2022506726A priority patent/JP7212222B2/ja
Priority to IL317912A priority patent/IL317912A/en
Priority to LTEPPCT/US2021/022779T priority patent/LT3989986T/lt
Priority to RS20250825A priority patent/RS67131B1/sr
Priority to KR1020237011866A priority patent/KR20230053705A/ko
Priority to US17/911,524 priority patent/US20230212255A1/en
Priority to PT217722081T priority patent/PT3989986T/pt
Priority to PE2022002042A priority patent/PE20231643A1/es
Priority to MX2022011554A priority patent/MX2022011554A/es
Priority to CA3169239A priority patent/CA3169239A1/en
Priority to HRP20251006TT priority patent/HRP20251006T1/hr
Priority to IL296473A priority patent/IL296473B2/en
Priority to NZ793365A priority patent/NZ793365A/en
Priority to KR1020227035401A priority patent/KR102520550B1/ko
Priority to PH1/2022/552463A priority patent/PH12022552463A1/en
Priority to AU2021238330A priority patent/AU2021238330B2/en
Priority to EP25182520.4A priority patent/EP4631525A3/en
Priority to BR112022018677A priority patent/BR112022018677A2/pt
Priority to ES21772208T priority patent/ES3039539T3/es
Priority to FIEP21772208.1T priority patent/FI3989986T3/fi
Priority to CR20220507A priority patent/CR20220507A/es
Priority to SI202130340T priority patent/SI3989986T1/sl
Priority to CN202180035520.4A priority patent/CN115955974A/zh
Priority to SM20250287T priority patent/SMT202500287T1/it
Publication of WO2021184673A1 publication Critical patent/WO2021184673A1/en
Priority to CL2022002522A priority patent/CL2022002522A1/es
Anticipated expiration legal-status Critical
Priority to DO2022000195A priority patent/DOP2022000195A/es
Priority to CONC2022/0014259A priority patent/CO2022014259A2/es
Priority to JP2022202035A priority patent/JP7624961B2/ja
Priority to AU2023200268A priority patent/AU2023200268A1/en
Priority to JP2025008195A priority patent/JP2025066770A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates to the field of bio-medicine, and more particularly to a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof.
  • Malignant tumors of the blood system account for about 10%of human malignant tumors, and 95%of malignant tumors of the blood system are derived from B lymphocytes.
  • Traditional chemotherapy and radiotherapy play an important role in the treatment of malignant tumors of the blood system.
  • Some patients have significant effects, but it is difficult for most of the patients to be cured. New and effective treatments have been a hot topic in this field.
  • CD19 is highly expressed on the surface of most B-cell malignancies. Multiple centers independently using Chimeric Antigen Receptor (CAR) -modified T cells to target recurrent, refractory malignant tumors of CD19-expressed B cell have achieved unprecedented success.
  • CAR Chimeric Antigen Receptor
  • CD19 chimeric antigen receptor (CAR) T cell therapy Although the efficacy of anti-CD19 CAR-T is outstanding, many studies have shown that there are also many problems with CD19 chimeric antigen receptor (CAR) T cell therapy. There are still some patients with poor treatment results and easy to relapse. The reasons for this include the susceptibility of tumor cells to antigen escape. For example, a recent experiment of CD19 CAR-cell therapy showed that 90%of patients achieved complete remission, but 11%of these patients eventually relapsed, and the relapsing patients were mainly patients with CD19-negative tumor.
  • CAR chimeric antigen receptor
  • An object of the present invention is to provide a method for effectively treating tumors and preventing antigen escape.
  • An object of the present invention is to provide a combined chimeric antigen receptor targeting CD19 and CD20 and preparation method thereof.
  • the present invention provides a sequence of the combined chimeric antigen receptor targeting CD19 and CD20 as well as a preparation method and activity identification of the modified T cell (CART-19/20) thereof.
  • the present invention provides a chimeric antigen receptor structure for use in the treatment of CD19 and CD20 positive B cell lymphoma.
  • the present disclosure provides for a bispecific chimeric antigen receptor (CAR) .
  • the bispecific CAR may comprise: (i) an anti-CD20 antigen-binding region which comprises a light chain variable region (V L 1) and a heavy chain variable region (V H 1) having amino acid sequences set forth in SEQ ID NO: 4 and SEQ ID NO: 3, respectively; and (ii) an anti-CD19 antigen-binding region which comprises a light chain variable region (V L 2) and a heavy chain variable region (V H 2) having amino acid sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6, respectively.
  • V L 1 is located at the N-terminus of V H 1.
  • V H 2 is located at the N-terminus of V L 2.
  • the anti-CD20 antigen-binding region may be a single-chain variable fragment (scFv) that specifically binds CD20.
  • the anti-CD19 antigen-binding region may be a scFv that specifically binds CD19.
  • the scFv that specifically binds CD20 is located at the N-terminus of the scFv that specifically binds CD19.
  • the bispecific CAR may further comprise: (a) a leader sequence, (b) a hinge region, (c) a transmembrane domain, (d) at least one co-stimulatory signaling region, (e) a cytoplasmic signaling domain, or (f) a combination thereof.
  • the co-stimulatory signaling region may be derived from 4-1BB (CD137) , CD28, OX40, CD2, CD7, CD27, CD30, CD40, CD70, CD134, PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a/CD18) , ICOS (CD278) , NKG2D, GITR, TLR2, or combinations thereof.
  • the cytoplasmic signaling domain may be derived from CD3 ⁇ .
  • the hinge region may be derived from Ig4, CD8, CD28, CD137, or combinations thereof.
  • the transmembrane domain may be derived from CD8, CD28, CD3 ⁇ , CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or combinations thereof.
  • the bispecific CAR may have an amino acid sequence set forth in SEQ ID NO: 16.
  • the present disclosure provides for an immune cell expressing the present bispecific CAR.
  • the immune cell may be a T cell or a natural killer (NK) cell.
  • the immune cell may be allogeneic or autologous.
  • nucleic acid encoding the present bispecific CAR.
  • the present disclosure further provides for a vector comprising the present nucleic acid.
  • the present disclosure provides for a method of treating cancer.
  • the method may comprise administering the immune cell to a subject in need thereof.
  • the cancer may be a hematologic cancer.
  • the cancer may be a B-cell malignancy.
  • the cancer may be Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, leukemia, and/or multiple myeloma.
  • the cancer may be acute myeloid leukemia (AML) , multiple myeloma (MM) , chronic lymphocytic leukemia (CLL) , chronic myelogenous leukemia, acute lymphoblastic leukemia (ALL) , diffuse large B cell lymphoma (DLBCL) , or combinations thereof.
  • AML acute myeloid leukemia
  • MM multiple myeloma
  • CLL chronic lymphocytic leukemia
  • ALL acute lymphoblastic leukemia
  • DLBCL diffuse large B cell lymphoma
  • a chimeric antigen receptor (CAR) , wherein the structure of the chimeric antigen receptor is shown in formula I as below:
  • each "-" is independently a linker peptide or a peptide bond
  • L is an optional signal peptide sequence
  • I is a flexible linker
  • H is an optional hinge region
  • TM is a transmembrane domain
  • C is a co-stimulatory signaling molecule
  • CD3 ⁇ is a cytoplasmic signaling sequence derived from CD3 ⁇
  • one of scFv1 and scFv2 is an antigen binding domain targeting CD19, and the other is an antigen binding domain targeting CD20.
  • the scFv1 is an antigen binding domain targeting CD20
  • the scFv2 is an antigen binding domain targeting CD19.
  • the structure of the antigen binding domain targeting CD20 is shown in formula A or B as below:
  • V H1 is an anti-CD20 antibody heavy chain variable region
  • V L1 is an anti-CD20 antibody light chain variable region
  • “-” is a linker peptide or a peptide bond.
  • the structure of the antigen binding domain targeting CD20 is shown in formula B.
  • amino acid sequence of the V H1 is shown in SEQ ID NO: 1
  • amino acid sequence of the V L1 is shown in SEQ ID NO: 2; or
  • amino acid sequence of the V H1 is shown in SEQ ID NO: 3
  • amino acid sequence of the V L1 is shown in SEQ ID NO: 4.
  • V H1 and V L1 are linked with a flexible linker (or a linker peptide) , and the flexible linker (or the linker peptide) is 1-4, preferably 2-4, more preferably 3-4 consecutive sequences as shown in SEQ ID NO: 7 (GGGGS) .
  • V L1 and V H1 are linked with a flexible linker as shown in SEQ ID NO: 19.
  • the structure of the antigen binding domain targeting CD19 is shown in formula C or D as below:
  • V L2 is an anti-CD19 antibody light chain variable region
  • V H2 is an anti-CD19 antibody heavy chain variable region
  • “-” is a linker peptide or a peptide bond.
  • the structure of the antigen binding domain targeting CD19 is shown in formula D.
  • amino acid sequence of the V L2 is shown in SEQ ID NO: 5
  • amino acid sequence of the V H2 is shown in SEQ ID NO: 6.
  • V H2 and V L2 are linked with a flexible linker (or a linker peptide) , and the flexible linker (or the linker peptide) is 1-4, preferably 2-4, more preferably 3-4 consecutive sequence as shown in SEQ ID NO: 7 (GGGGS) .
  • V H2 and V L1 are linked with a flexible linker as shown in SEQ ID NO: 20.
  • the scFv1 and/or scFv2 are mouse-derived, humanized, humanized and mouse-derived chimeric, or fully humanized single chain antibody variable region fragments.
  • the structure of the chimeric antigen receptor is shown in formula II as below:
  • sequence of the flexible linker I comprises 2-6, preferably 3-4 consecutive sequences as shown in SEQ ID NO: 7 (GGGGS) .
  • sequence of the flexible linker I is as shown in SEQ ID NO: 7.
  • the L is a signal peptide of a protein selected from the group consisting of CD8, CD28, GM-CSF, CD4, CD137, and a combination thereof.
  • the L is a signal peptide derived from CD8.
  • amino acid sequence of the L is shown in SEQ ID NO: 8.
  • the H is a hinge region of a protein selected from the group consisting of CD8, CD28, CD137, Ig4, and a combination thereof.
  • the H is a hinge region derived from Ig4.
  • amino acid sequence of the H is shown in SEQ ID NO: 9.
  • the TM is a transmembrane region of a protein selected from the group consisting of CD28, CD3 ⁇ , CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and a combination thereof.
  • the TM is a transmembrane region derived from CD8 or CD28.
  • sequence of the TM is shown in SEQ ID NO: 10 or 11.
  • the C is a co-stimulatory signaling molecule of a protein selected from the group consisting of OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137) , PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a/CD18) , ICOS (CD278) , NKG2D, GITR, TLR2, and a combination thereof.
  • a protein selected from the group consisting of OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137) , PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a/CD18) , ICOS (CD278) , NKG2D, GITR, TLR2, and a combination thereof.
  • the C is a co-stimulatory signaling molecule derived from 4-1BB or CD28.
  • amino acid sequence of the C is shown in SEQ ID NO: 12 or 13.
  • amino acid sequence of the CD3 ⁇ is shown in SEQ ID NO: 14.
  • amino acid sequence of the CAR is shown in SEQ ID NO: 15 or 16.
  • the anti-CD20 antigen-binding region includes a heavy chain variable region comprising an amino acid sequence at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%identical to the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 1.
  • the anti-CD20 antigen-binding region includes a light chain variable region comprising an amino acid sequence at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%identical to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 2.
  • the anti-CD19 antigen-binding region includes a heavy chain variable region comprising an amino acid sequence at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%identical to the amino acid sequence set forth in SEQ ID NO: 6.
  • the anti-CD19 antigen-binding region includes a light chain variable region comprising an amino acid sequence at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%identical to the amino acid sequence set forth in SEQ ID NO: 5.
  • a heavy chain variable region of the anti-CD20 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a heavy chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3
  • a light chain variable region of the anti-CD20 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a light chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3
  • a heavy chain variable region of the anti-CD20 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a heavy chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3
  • a light chain variable region of the anti-CD20 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a light chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3
  • a heavy chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to CDRs of a heavy chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3 as set forth in position 30-35, position 50-66, position 99-111 of SEQ ID NO: 3)
  • a light chain variable region of the anti-CD20 antigen- binding region includes three CDRs that are identical to CDRs of a light chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3 as set forth in position 24-34, position 50-56, position 89-97 of SEQ ID NO: 4, respectively) .
  • a heavy chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to the CDRs of a heavy chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, respectively)
  • a light chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to the CDRs of a light chain variable region of the Ofatumumab antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, respectively) .
  • a heavy chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to CDRs of a heavy chain variable region of the Leu16 antibody (CDR1, CDR2 and CDR3 as set forth in position 31-35, position 50-66, position 99-111 of SEQ ID NO: 1, respectively)
  • a light chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to CDRs of a light chain variable region of the Leu16 antibody (CDR1, CDR2 and CDR3 as set forth in position 24-33, position 49-55, position 88-96 of SEQ ID NO: 2, respectively) .
  • a heavy chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to CDRs of a heavy chain variable region of the Leu16 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, respectively)
  • a light chain variable region of the anti-CD20 antigen-binding region includes three CDRs that are identical to CDRs of a light chain variable region of the Leu16 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, respectively) .
  • a heavy chain variable region of the anti-CD19 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a heavy chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth
  • a light chain variable region of the anti-CD19 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a light chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth
  • a heavy chain variable region of the anti-CD19 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a heavy chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth
  • a light chain variable region of the anti-CD19 antigen-binding region can comprise one, two, or three complementarity determining regions (CDRs) that are at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 99%, at least or about 81%, at least or about 82%, at least or about 83%, at least or about 84%, at least or about 85%, at least or about 86%, at least or about 87%, at least or about 88%, at least or about 89%, at least or about 90%, at least or about 91%, at least or about 92%, at least or about 93%, at least or about 94%, at least or about 95%, at least or about 96%, at least or about 97%, at least or about 98%, at least or about 99%, or about 100%, identical to the CDRs of a light chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth
  • a heavy chain variable region of the anti-CD19 antigen-binding region includes three CDRs that are identical to CDRs of a heavy chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth in position 31-35, position 50-65, position 98-109 of SEQ ID NO: 6, respectively)
  • a light chain variable region of the anti-CD19 antigen-binding region includes three CDRs that are identical to CDRs of a light chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth position 24-34, position 50-56, position 89-97 of SEQ ID NO: 5 respectively) .
  • a heavy chain variable region of the anti-CD19 antigen-binding region includes three CDRs that are identical to CDRs of a heavy chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth in SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, respectively)
  • a light chain variable region of the anti-CD19 antigen-binding region includes three CDRs that are identical to CDRs of a light chain variable region of the FMC63 antibody (CDR1, CDR2 and CDR3 as set forth SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 39, respectively) .
  • nucleic acid molecule encoding the chimeric antigen receptor of the first aspect of the invention.
  • the nucleic acid molecule is isolated.
  • nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO: 17 or 18.
  • a vector comprising the nucleic acid molecule of the second aspect of the invention.
  • the vector comprises DNA and RNA.
  • the vector is selected from the group consisting of plasmid, virus vector, transposon, and a combination thereof.
  • the vector comprises a DNA virus and a retrovirus vector.
  • the vector is selected from the group consisting of a lentiviral vector, an adenovirus vector, an adeno-associated virus vector, and a combination thereof.
  • the vector is a lentiviral vector.
  • a host cell comprising the vector of the third aspect of the invention or having the exogenous nucleic acid molecule of the second aspect of the invention integrated into its genome or expressing the chimeric antigen receptor of the first aspect of the invention.
  • the cell is an isolated cell.
  • the cell is a genetically engineered cell.
  • the cell is a mammalian cell.
  • the cell is a CAR-T cell and/or a CAR-NK cell.
  • the cell targets both CD19 and CD20.
  • a fifth aspect of the invention provides a method for preparing a CAR-T cell expressing the chimeric antigen receptor of the first aspect of the invention, wherein the method comprises the steps of: transducing the nucleic acid molecule of the second aspect of the invention or the vector of the third aspect of the invention into a T cell, thereby obtaining the CAR-T cell.
  • the method further comprises the step of detecting the function and effectiveness of the obtained CAR-T cell.
  • a preparation comprising the chimeric antigen receptor of the first aspect of the invention, the nucleic acid molecule of the second aspect of the invention, the vector of the third aspect of the invention, or the host cell of the fourth aspect of the invention, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the preparation is a liquid preparation.
  • the formulation of the preparation is an injection.
  • the preparation comprises the host cell of the fourth aspect of the invention, and the concentration of the host cell is 1 ⁇ 10 3 -1 ⁇ 10 8 cells/ml, preferably 1 ⁇ 10 4 -1 ⁇ 10 7 cells/ml.
  • a seventh aspect of the invention provides the use of the chimeric antigen receptor of the first aspect of the invention, the nucleic acid molecule of the second aspect of the invention, the vector of the third aspect of the invention, or the host cell of the fourth aspect of the invention, for the preparation of a medicine or a formulation for preventing and/or treating tumor or cancer.
  • the tumor is selected from the group consisting of a hematological tumor, a solid tumor, and a combination thereof; preferably, the tumor is a hematological tumor.
  • the blood tumor is selected from the group consisting of acute myeloid leukemia (AML) , multiple myeloma (MM) , chronic lymphocytic leukemia (CLL) , acute lymphoblastic leukemia (ALL) , diffuse large B cell lymphoma (DLBCL) , and a combination thereof.
  • AML acute myeloid leukemia
  • MM multiple myeloma
  • CLL chronic lymphocytic leukemia
  • ALL acute lymphoblastic leukemia
  • DLBCL diffuse large B cell lymphoma
  • the solid tumor is selected from the group consisting of gastric cancer, peritoneal metastasis of gastric cancer, liver cancer, leukemia, renal cancer, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, large intestine cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC) , glioma, endometrial cancer, and a combination thereof.
  • gastric cancer peritoneal metastasis of gastric cancer
  • liver cancer leukemia, renal cancer, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, large intestine cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC) , glioma, endometrial cancer, and a combination thereof.
  • NSCLC non
  • kits for the preparation of the cell of the fourth aspect of the invention wherein the kit comprises a container, and the nucleic acid molecule of the second aspect of the invention or the vector of the third aspect of the invention located in the container.
  • a ninth aspect of the invention provides a use of the cell of the fourth aspect of the invention, or the formulation of the sixth aspect of the invention for the prevention and/or treatment of cancer or tumor.
  • a tenth aspect of the invention provides a method of treating a disease comprising administering an appropriate amount of the cell of the forth aspect of the invention, or the formulation of the sixth aspect of the invention, to a subject in need of treatment.
  • the disease is cancer or tumor.
  • Figure 1 shows structure of the combined chimeric antigen receptor targeting CD19 and CD20.
  • the structure of the CAR comprises a leader sequence, an antigen recognition sequence, a hinge region, a transmembrane region, a co-stimulatory factor signal region, and a CD3 ⁇ signaling region.
  • Figures 2A and 2B show the expression level of CD137 on the surface of T cell membrane (Fig. 2A) and the secretion level of IFN ⁇ in the culture supernatant (Fig. 2B) .
  • 1 ⁇ 10 5 of CAR-T19/20s cells cultured 7 days were taken and cultured respectively with CD19-positive K562-CD19+ tumor cell line, CD20-positive K562-CD20+ tumor cell line, CD19 and CD20 double positive K562-CD19+CD20+ tumor cell line, RAJI tumor cell line that naturally expresses CD19 and CD20, and CD19 and CD20 double negative K562 tumor cell line, or without tumor cells, in 200 ⁇ l of GT-551 medium for 18h with a ratio of 1: 1. Then the expression level of CD137 on the surface of T cell membrane and the secretion level of IFN ⁇ in the culture supernatant were detected respectively.
  • Figure 3A shows the detection of tumor-killing activity of CAR-T19/20s cells, mainly by detecting the secretion level of LDH in the supernatant after co-culture.
  • 1 ⁇ 10 4 cells of CD19-positive K562-CD19+ tumor cell line, CD20-positive K562-CD20+ tumor cell line, CD19 and CD20 double positive K562-CD19+ CD20+ tumor cell line, RAJI or RAMOS tumor cell line that naturally expresses CD19 and CD20, or CD19 and CD20 double negative K562 tumor cell line were co-cultured with the corresponding T cells, respectively, in 100 ⁇ l of GT-551 medium for 8h with a ratio as shown in the figure. Then the secretion level of LDH was detected, and this figure shows the statistical analysis results of the percentages of LDH release in corresponding co-culture samples.
  • Figure 3B shows the detection of tumor-killing activity of CAR-T19/20s cells, mainly by detecting the expression level of CD107a on the surface of T cell membrane.
  • 1 ⁇ 10 5 CAR-T19/20s cells were taken and cultured respectively with CD19-positive K562-CD19+ tumor cell line, CD20-positive K562-CD20+ tumor cell line, CD19 and CD20 double positive K562- CD19+CD20+ tumor cell line, RAJI or RAMOS tumor cell line that naturally expresses CD19 and CD20, and CD19 and CD20 double negative K562 tumor cell line, or without tumor cells, in 200 ⁇ l of GT-551 medium for 4h with a ratio of 1: 2. Then the expression level of CD137 on the surface of T cell membrane was detected respectively.
  • Figure 4A shows the average body weight changes and average fluorescence intensity changes of mice injected with CAR-T19/20s cells within 21 days, which are recorded every 7 days.
  • Figure 4B shows the average fluorescence intensity of the three groups of mice.
  • Figure 4C shows in vivo imaging of mice injected with CAR-T19/20s cells on day 0 (D0) , 7 (D7) , 14 (D14) , and 21 (D21) after injection.
  • Figure 5A shows that bi-specific TN-OF-19 CAR-T cells can inhibit or kill tumor cells better than CD19 specific CAR-T cells in vivo.
  • Figure 5B shows the IVIS imaging of fluorescence intensity in 4 CAR-T cell groups and NT group.
  • Figure 6 shows the chimeric antibody bound to cells with CD19 or CD20 or both, but not to cells lacking both antigens, indicating that the bispecific binding domain required only one cognate antigen for binding and no new specific recognition sites were formed
  • Figure 7 shows the structures of sixteen CD20 specific CARs with six different scFVs and different hinge/TM/signaling domains.
  • Figure 8A shows the results of IFN ⁇ release assay to screen CAR-T20.1, CAR-T20.5, CAR-T20.6, CAR-T20.7, CAR-T20.8, CAR-T20.9 and CAR-T20.10, and among these CAR-Ts, only CAR-T20.9 (Leu16) and CAR-T20.10 (Leu16) showed higher positive IFN ⁇ release.
  • Figure 8B shows the results of IFN ⁇ release assay to screen CAR-T20.1, CAR-T20.9, CAR-T20.10, CAR-T20.11, CAR-T20.12, CAR-T20.13, CAR-T20.14, CAR-T20.15 and CAR-T20.16.
  • CAR-T20.10 Leu16
  • CAR-T20.14 OF
  • Figure 8C shows the results of IFN ⁇ release assay to screen CAR-T20.9, CAR-T20.12, CAR-T20.14, CAR-T20.17, CAR-T20.18, and CAR-T20.19.
  • CAR-T20.14 (OF) and CAR-T20.19 (OF) showed higher positive IFN ⁇ release.
  • Figure 9A shows the results of CAR-T20.17 (Leu16 3 rd generation) , CAR-T20.18 (Leu16 2 nd generation) , CAR-T20.19 (OF 2 nd generation) cells tested for cytotoxicity by LDH release assay.
  • Figure 9B shows the in vivo inhibition of tumor growth in NSG mouse studies.
  • the tumor cells injected in animals are Raji expressing luciferase.
  • Figure 10 shows CAR039 r/rNHL study design and flow chart.
  • FIG 11 shows the summary of C-CAR039 clinical results.
  • Figure 12 shows examples of patient before and post C-CAR039 treatment.
  • FIG 13 shows C-CAR039 proliferation and expansion in patient’s blood. The results showed that C-CAR008 cells expanded effectively after injection.
  • Figure 14 shows the C-CAR066-NHL study design.
  • Figure 15 shows an example of PET-CT of a patient before and after treated with C-CAR066.
  • the present invention provides a chimeric antigen receptor that simultaneously targets CD19 and CD20, which comprises a signal peptide, an anti-CD20 scFv, an anti-CD19 scFv, a hinge region, a transmembrane region, and an intracellular T cell signaling region.
  • the anti-CD20 scFv and anti-CD19 scFv were obtained through a large number of screenings, which were linked with peptide fragment with multiple repeat structure (G4S) .
  • the CAR-T cells of the present invention can recognize both CD19 and CD20 antigens at the same time, reducing the risk of immune escape caused by down-regulation or deletion of antigen expression during the treatment of single-target CAR-T cells.
  • the CAR-T cells of the present invention that simultaneously recognize two targets have stronger killing ability against tumor cells, less cytotoxicity, lower side effects, wider treatment range, lower recurrence rate and better efficacy.
  • the present invention has been completed on the basis of this.
  • administering refers to the physical introduction of a product of the invention into a subject using any one of various methods and delivery systems known to those skilled in the art, including intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral administration, such as by injection or infusion.
  • antibody may comprise, but is not limited to, an immunoglobulin that specifically binds an antigen and contains at least two heavy (H) chains and two light (L) chains linked by disulfide bonds, or an antigen binding parts thereof.
  • H chain contains a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
  • the heavy chain constant region contains three constant domains, CH1, CH2, and CH3.
  • Each light chain contains a light chain variable region (abbreviated herein as VL) and a light chain constant region.
  • the light chain constant region contains a constant domain CL.
  • VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDR) , which are interspersed within more conservative regions called framework regions (FR) .
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL contains three CDRs and four FRs, which are arranged from amino terminal to carboxy terminal in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • CAR chimeric antigen receptor
  • the inventors design a combined bispecific CAR (i.e., BICAR) that targets both CD19 and CD20, so that when CD19 antigen escapes and is not expressed in tumor cells, CD20 can be recognized to clear tumor cells in vivo.
  • BICAR bispecific CAR
  • CD20 is expressed in most patients with B-cell acute lymphoblastic leukemia, including some CD19 negative patients after anti-CD19 CAR-T treatment.
  • CD20 is a glycosylated protein, and is the first identified B cell membrane marker.
  • CD20 is also known as B1, and encoded by the MS4A gene.
  • CD20 molecule has four transmembrane hydrophobic regions, and its N-terminal and C-terminal are located on the cytoplasmic side, forming two closed loops outside the cell, and respectively called big loop and small loop.
  • CD20 is specifically expressed in more than 95%of normal and cancerous B cells. These cells are in the pre-B cell stage and subsequent developmental stages, and CD20 stops expression until the cells differentiated into plasma cells.
  • the present invention uses CD20 as another target for immunotherapy of B cell malignancies.
  • Cellular immunotherapy is an emerging and highly effective tumor treatment model, and is a new type of autoimmunolgy treatment for cancer. It is a method for in vitro culture and amplification of immune cells collected from a patient using biotechnology and biological agents, and then the cells are transfused back to the patient to stimulate and enhance the body's autoimmune function, thereby achieving the purpose of treating tumors.
  • the skilled in the art have been working to develop new cellular immunotherapy to increase the efficiency and reduce the side effect.
  • the present invention proposes a rational and optimized single-chain design and system, that is, combined bispecific CAR, which can be effectively integrated into primary human T cells, and can simultaneously target CD19 and CD20 when the T cells are activated.
  • the CAR-T cells of the invention are capable of recognizing two antigens (CD19 and CD20) .
  • the invention provides a very effective potential method for preventing antigen escape.
  • the present invention uses CAR that simultaneously targets CD19 and CD20. Compared with CARs that target a single antigen, the affinity is enhanced, the activity of T cells is increased, and the targets have an additive or synergistic effect. In addition, due to uneven expression levels of CD19 and CD20 in tumor cells, double target CAR-T therapy has a wider scope.
  • the CAR-T that simultaneously targets CD19 and CD20 on the surface of tumor cells can reduce the possibility of antigen escape caused by down-regulation or deletion of single surface antigen.
  • Bispecificity means that the same CAR can specifically bind and immunorecognize two different antigens, and the CAR can generate an immune response by binding to any one of the antigens.
  • the CD19 and CD20 bispecific CAR of the present invention has a single structure and comprises anti-CD19 and anti-CD20 scFvs.
  • the CAR comprises a CD19 scFv and a CD20 scFv, and the amino acid sequences, sequencing and hinge of CD19 scFv and CD20 scFv are the main factors affecting its function.
  • the chimeric antigen receptor (CAR) of the invention comprises an extracellular domain, a transmembrane domain, and an intracellular domain.
  • the extracellular domain comprises a target-specific binding element (also known as an antigen binding domain) .
  • the intracellular domain comprises a co-stimulatory signaling region and a ⁇ chain.
  • the co-stimulatory signaling region refers to a part of the intracellular domain that comprises a co-stimulatory molecule.
  • the co-stimulatory molecule is a cell surface molecule required for efficient response of lymphocytes to antigens, rather than an antigen receptor or ligand thereof.
  • a linker can be incorporated between the extracellular domain and the transmembrane domain of the CAR, or between the cytoplasmic domain and the transmembrane domain of the CAR.
  • the term "linker” generally refers to any oligopeptide or polypeptide that plays a role of linking the transmembrane domain to the extracellular domain or the cytoplasmic domain in a polypeptide chain.
  • the linker may comprise 0-300 amino acids, preferably 2-100 amino acids and most preferably 3-50 amino acids.
  • the extracellular domain of the CAR provided in the present invention comprises an antigen binding domain targeting CD19 and CD20.
  • antigen recognition can be performed based on antigen binding specificity.
  • the CAR binds to its associated antigen, it affects tumor cell, causing tumor cell to fail to grow, to death or to be affected otherwise, causing the patient's tumor burden to shrink or eliminate.
  • the antigen binding domain is preferably fused to the intracellular domain from one or more of the co-stimulatory molecule and the ⁇ chain.
  • the antigen binding domain is fused with an intracellular domain of a combination of a 4-1BB signaling domain and a CD3 ⁇ signaling domain.
  • the “antigen binding domain” and “single-chain antibody fragment” refer to an Fab fragment, an Fab’ fragment, an F (ab’) 2 fragment, or a single Fv fragment that has antigen-binding activity.
  • the Fv antibody contains the heavy chain variable region and the light chain variable region of the antibody, but has no constant region.
  • the Fv antibody has the smallest antibody fragment with all antigen-binding sites.
  • Fv antibodies also comprise a polypeptide linker between the VH and VL domains, and can form the structure required for antigen binding.
  • the antigen binding domain is usually a scFv (single-chain variable fragment) .
  • the size of scFv is typically 1/6 of a complete antibody.
  • the single-chain antibody is preferably an amino acid chain sequence encoded by a nucleotide chain.
  • the scFv comprises antibodies that specifically recognize CD19 and CD20.
  • the CAR can be designed to comprise a transmembrane domain fused to the extracellular domain of the CAR.
  • a transmembrane domain that is naturally associated with one of the domains in the CAR is used.
  • transmembrane domains may be selected or modified by amino acid substitutions to avoid binding such domains to the transmembrane domain of the same or different surface membrane proteins, thereby minimizing the interaction with other members of the receptor complexes.
  • the intracellular domain in the CAR of the invention comprises the signaling domain of 4-1BB and the signaling domain of CD3 ⁇ .
  • the CAR structure of the present invention comprises a signal peptide sequence (also known as leader sequence) , an antigen recognition sequence (antigen-binding domain) , a hinge region, a transmembrane region, a co-stimulatory factor signal region, and a CD3zeta signaling region ( ⁇ chain portion) .
  • a signal peptide sequence also known as leader sequence
  • an antigen recognition sequence antigen-binding domain
  • a hinge region a transmembrane region
  • co-stimulatory factor signal region a co-stimulatory factor signal region
  • CD3zeta signaling region ⁇ chain portion
  • the present CAR is TN-LEU-19.
  • the antigen binding domain targeting CD20 comprises a heavy chain sequence (SEQ ID NO: 1) and a light chain (VL) sequence (SEQ ID NO: 2) of the single-chain variable region derived from Leu16 antibody.
  • VH Heavy chain sequence of single-chain variable region (VH) derived from Leu16 antibody:
  • LEU-VH-CDR1 SEQ ID NO: 1, position 31-35;
  • LEU -VH-CDR2 SEQ ID NO: 1, position 50-66;
  • LEU -VH-CDR3 SEQ ID NO: 1, position 99-111.
  • VL Light chain sequence of single-chain variable region (VL) derived from Leu16 antibody:
  • LEU-VL-CDR1 SEQ ID NO: 2, position 24-33;
  • LEU -VL-CDR2 SEQ ID NO: 2, position 49-55;
  • LEU -VL-CDR3 SEQ ID NO: 2, position 88-96.
  • the present CAR is TN-OF-19.
  • the antigen binding domain targeting CD20 comprises a heavy chain sequence (SEQ ID NO: 3) and a light chain sequence (SEQ ID NO: 4) of the single-chain variable region derived from Ofatumumab antibody.
  • VH Heavy chain sequence of single-chain variable region (VH) derived from Ofatumumab antibody:
  • OF-VH-CDR1 SEQ ID NO: 3, position 30-35.
  • the sequence of OF-VH-CDR1 is: NDYAMH (SEQ ID NO: 40) .
  • OF-VH-CDR2 SEQ ID NO: 3, position 50-66.
  • the sequence of OF-VH-CDR2 is: TISWNSGSIGYADSVKG (SEQ ID NO: 41) .
  • OF-VH-CDR3 SEQ ID NO: 3, position 99-111.
  • the sequence of OF-VH-CDR3 is: DIQYGNYYYGMDV (SEQ ID NO: 42) .
  • VL Light chain sequence of single-chain variable region (VL) derived from Ofatumumab antibody:
  • OF-VL-CDR1 SEQ ID NO: 4, position 24-34.
  • the sequence of OF-VL-CDR1 is: RASQSVSSYLA (SEQ ID NO: 43) .
  • OF-VL-CDR2 SEQ ID NO: 4, position 50-56.
  • the sequence of OF-VL-CDR2 is: DASNRAT (SEQ ID NO: 44) .
  • OF-VL-CDR3 SEQ ID NO: 4, position 89-97.
  • the sequence of OF-VL-CDR3 is: QQRSNWPIT (SEQ ID NO: 45) .
  • the antigen-binding domain targeting CD19 in the CAR of the present invention comprises a light chain (VL) sequence (SEQ ID NO: 5) and a heavy chain sequence (SEQ ID NO: 6) of the single-chain variable region derived from FMC63 antibody.
  • VL light chain
  • SEQ ID NO: 6 heavy chain sequence
  • VL single-chain variable region
  • FMC63-VL-CDR1 SEQ ID NO: 5, position 24-34.
  • the sequence of FMC63-VL-CDR1 is: RASQDISKYLN (SEQ ID NO: 63) .
  • FMC63-VL-CDR2 SEQ ID NO: 5, position 50-56.
  • the sequence of FMC63-VL-CDR2 is: HTSRLHS (SEQ ID NO: 64) .
  • FMC63-VL-CDR3 SEQ ID NO: 5, position 89-97.
  • the sequence of FMC63-VL-CDR3 is: QQGNTLPYT (SEQ ID NO: 39) .
  • VH single-chain variable region
  • FMC63-VH-CDR1 SEQ ID NO: 6, position 31-35.
  • the sequence of FMC63-VH-CDR1 is: DYGVS (SEQ ID NO: 60) .
  • FMC63-VH-CDR2 SEQ ID NO: 6, position 50-65.
  • the sequence of FMC63-VH-CDR2 is: VIWGSETTYYNSALKS (SEQ ID NO: 61) .
  • FMC63-VH-CDR3 SEQ ID NO: 6, position 98-109.
  • the sequence of FMC63-VH-CDR3 is: HYYYGGSYAMDY (SEQ ID NO: 62) .
  • VH single-chain variable region
  • sequences of other elements in the CAR of the present invention are as follows:
  • the leader sequence is the leader sequence of CD8 antigen:
  • linker sequences i.e., flexible linker I between the heavy chain and light chain of the single-chain variable region are:
  • the hinge region is selected from the sequence of a short form of IgG4 Hinge:
  • the transmembrane region is the transmembrane region sequence of CD8 (CD8TM) or CD28 (CD28TM) antigen:
  • CD8TM IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 10)
  • CD28TM MFWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 11)
  • the co-stimulatory factor signal region is derived from the sequence of 4-1BB or CD28 cytoplasmic signaling motif:
  • CD28 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO: 13)
  • the signaling region of CD3 ⁇ is derived from the sequence of immunoreceptor tyrosine-based activation motif (ITAM) of CD3 ⁇ in the TCR complex:
  • nucleic acid sequences and amino acid sequences of the two CARs constructed in the present invention are as follows:
  • TN-OF-19 The complete nucleic acid sequence of TN-OF-19 is as follows:
  • TN-LEU-19 The complete nucleic acid sequence of TN-LEU-19 is as follows:
  • TN-LEU-19 The complete amino acid sequence of TN-LEU-19 is as follows:
  • the design of the BICAR of the present invention has the following advantages:
  • CD19 and CD20 are expressed in most malignant B-cell tumors.
  • problems such as increased adverse targeting, increased cytotoxicity, and increased side effects are often encountered.
  • CD19 and CD20 because both of them are only expressed in B cells with the same tumor toxicity curve.
  • the expression of CD19 and CD20 in B cells can promote the survival of B cells.
  • the loss of both antigens during treatment is a very low probability event. Therefore, targeting CD19 and CD20 is expected to provide effective prevention of antigen escape of malignant B cells.
  • BICAR Compared with the single CAR of CD19 or CD20, BICAR has the following advantages:
  • the DNA footprint is significantly reduced (the DNA length is reduced by 40%) .
  • the size and the length of structure can significantly affect the packaging and transduction efficiency of the viral vector, thus directly affecting the clinical efficacy.
  • BICAR can significantly reduce the cost of treatment (BICAR is completely compatible with the current T cell production process without adding additional burden. ) and increase the clinical cure rate.
  • CD19 and CD20 have been verified in a large number of clinical studies and are relatively safe.
  • chimeric antigen receptor structures (TN-LEU-19, TH-OF-19) targeting CD19 and CD20 based on the sequence of CD19 mouse-derived monoclonal antibody FMC63 and the sequences of CD20 mouse-derived monoclonal antibody leu-16 and Ofatumumab.
  • FMC63 the sequence of CD19 mouse-derived monoclonal antibody
  • CD20 mouse-derived monoclonal antibody leu-16 and Ofatumumab
  • T-cells modified with TN-LEU-19 or TH-OF-19 chimeric antigen receptors have a strong ability to kill in vitro and to clear malignant tumors carrying CD19 and CD20 positive antigens in vivo, and Ofatumumab is better than leu16. This provides a new effective method and preparation for the clinical application of CAR-T in the treatment of CD19 and CD20-positive leukemias and lymphomas.
  • the present invention designed and optimized single-specific and double-specific CARs. These CARs have a powerful killing ability against B-cell malignancies expressing CD19 or CD20.
  • BICAR allows a single T-cell product to target two clinically validated antigens associated with B-cell leukemia and lymphoma, ultimately reducing the risk of tumor recurrence due to the loss or escape of a single antigen.
  • the invention can be further used in the design of new BICAR, thus increasing the antigen's applicability and increasing the efficacy of T cell therapy for cancer.
  • the terms "CAR-T cell” , “CAR-T” , “CART” , “CAR-T cell of the present invention” all refer to the CAR-T cell that targets both CD19 and CD20 of the forth aspect of the invention.
  • the CAR structure of the CAR-T cells comprises an anti-CD19 scFv, an anti-CD20 scFv, a hinge region, a transmembrane region, and an intracellular T cell signaling region in turn, wherein the anti-CD20 scFv and anti-CD19 scFv are linked with a peptide having multiple repeating structures (G4S) .
  • G4S multiple repeating structures
  • nucleic acid sequences coding for the desired molecules can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to comprise the same, or by isolating directly from cells and tissues containing the same, using standard techniques.
  • the gene of interest can be produced synthetically.
  • the present invention also provides vectors in which the expression cassette of the present invention is inserted.
  • Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells.
  • Lentiviral vectors have the advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the advantage of low immunogenicity.
  • the expression cassette or nucleic acid sequence of the invention is typically and operably linked to a promoter, and incorporated into an expression vector.
  • the vectors can be suitable for replication and integration in eukaryotes.
  • Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.
  • the expression constructs of the present invention may also be used for nucleic acid immune and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S, Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties.
  • the invention provides a gene therapy vector.
  • the nucleic acid can be cloned into a number of types of vectors.
  • the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid.
  • Vectors of particular interest comprise expression vectors, replication vectors, probe generation vectors, and sequencing vectors.
  • the expression vector may be provided to a cell in the form of a viral vector.
  • Viral vector technology is well known in the art and is described, for example, in Sambrook et al, (2001 , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) , and in other virology and molecular biology manuals.
  • Viruses, which are useful as vectors comprise, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses.
  • a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S, Pat. No. 6,326,193) .
  • retroviruses provide a convenient platform for gene delivery systems.
  • a selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art.
  • the recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo.
  • retroviral systems are known in the art.
  • adenovirus vectors are used.
  • a number of adenovirus vectors are known in the art.
  • lentivirus vectors are used.
  • promoter elements e.g., enhancers
  • promoters regulate the frequency of transcriptional initiation.
  • these are located in the region 30-1 10 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well.
  • the spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another, .
  • tk thymidine kinase
  • the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline.
  • individual elements can function either cooperatively or independently to activate transcription.
  • a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto.
  • CMV immediate early cytomegalovirus
  • EF-1 ⁇ Elongation Growth Factor-1 ⁇
  • constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV) , human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter.
  • SV40 simian virus 40
  • MMTV mouse mammary tumor virus
  • HSV human immunodeficiency virus
  • LTR long terminal repeat
  • MoMuLV promoter MoMuLV promoter
  • an avian leukemia virus promoter an Epstein-Barr virus immediate early promoter
  • Rous sarcoma virus promoter as well as human gene promoters
  • inducible promoters are also contemplated as part of the invention.
  • the use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired.
  • inducible promoters comprise, but are not limited to a metallothionein promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.
  • the expression vector to be introduced into a ceil can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors.
  • the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells.
  • Useful selectable markers comprise, for example, antibiotic-resistance genes, such as neo and the like.
  • Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences.
  • a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells.
  • Suitable reporter genes may comprise genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82) .
  • Suitable expression systems are well known and may be prepared using known techniques or obtained commercially.
  • the construct with the minimal 5’ flanking region showing the highest level of expression of reporter gene is identified as the promoter.
  • Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.
  • the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art.
  • the expression vector can be transferred into a host cell by physical, chemical, or biological means.
  • Physical methods for introducing a polynucleotide into a host cell comprise calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like.
  • Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) .
  • a preferred method for the introduction of a polynucleotide into a host cell is calcium phosphate transfection.
  • Biological methods for introducing a polynucleotide of interest into a host cell comprise the use of DNA and RNA vectors.
  • Viral vectors, and especially retroviral vectors have become the most widely used method for inserting genes into mammalian, e.g., human cells.
  • Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat, Nos. 5,350,674 and 5,585,362.
  • Chemical means for introducing a polynucleotide into a host cell comprise colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • colloidal dispersion systems such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle) .
  • an exemplary delivery vehicle is a liposome.
  • lipid formulations is contemplated for the introduction of the nucleic acids into a host cell (in vitro, ex vivo or in vivo) .
  • the nucleic acid may be associated with a lipid.
  • the nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid.
  • Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution.
  • Lipids are fatty substances which may be naturally occurring or synthetic lipids.
  • lipids comprise the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
  • the vector is a lentiviral vector.
  • the invention provides a preparation comprising the CAR-T cell of the forth aspect of the invention, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the preparation is a liquid preparation.
  • the preparation is an injection.
  • the concentration of the CAR-T cells in the preparation is 1 ⁇ 10 3 -1 ⁇ 10 8 cells /ml, more preferably 1 ⁇ 10 4 -1 ⁇ 10 7 cells /ml.
  • the preparation may comprises buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide) ; and preservatives.
  • buffers such as neutral buffered saline, phosphate buffered saline and the like
  • carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins polypeptides or amino acids
  • antioxidants such as glycine
  • chelating agents such as EDTA or glutathione
  • adjuvants e.g., aluminum hydroxide
  • preservatives e.g., aluminum hydroxide
  • the invention comprises therapeutic applications using cells (e.g., T cells) transduced with a lentiviral vector (LV) encoding the expression cassette of the invention.
  • the transduced T cells can target the tumor cell markers CD19 and CD20, synergistically activate T cells, and cause T cell immune responses, thereby significantly increasing the killing efficiency against tumor cells.
  • the present invention also provides a method for stimulating a T cell-mediated immune response to a target cell population or tissue in a mammal comprising the step of administering to the mammal a CAR-T cell of the invention.
  • the present invention comprises a class of cell therapies, wherein T cells from autologous patient (or heterologous donor) are isolated, activated and genetically modified to generate CAR-T cells, and then injected into the same patient.
  • T cells from autologous patient or heterologous donor
  • the probability of graft versus host disease in this way is extremely low, and antigens are recognized by T cells in a non-MHC-restricted manner.
  • one CAR-T can treat all cancers that express the antigen.
  • CAR-T cells are able to replicate in vivo resulting in long-term persistence that can lead to sustained tumor control.
  • the CAR-T cells of the invention can undergo robust in vivo T cell expansion and can persist for an extended amount of time.
  • the CAR mediated immune response may be part of an adoptive immunotherapy approach in which CAR-modified T cells induce an immune response specific to the antigen binding moiety in the CAR.
  • an anti-CD19CD20 CAR-T cell elicits an immune response specifically against cells expressing CD19 and CD20.
  • Cancers that may be treated comprise tumors that are unvascularized or largely unvascularized, and tumors that are vascularized. Cancers may comprise non-solid tumors (such as hematological tumors, for example, leukemias and lymphomas) or solid tumors. Types of cancers to be treated with the CARs of the invention comprise, but are not limited to, carcinoma, blastoma, and sarcoma, and certain leukemia or lymphoid malignancies, benign and malignant tumors, and malignancies e.g., sarcomas, carcinomas, and melanomas. Adult tumors/cancers and pediatric tumors/cancers are also comprised.
  • Hematologic cancers are cancers of the blood or bone marrow.
  • hematological (or hematogenous) cancers comprise leukemias, including acute leukemias (such as acute lymphocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia and myeloblasts, promyeiocytic, myelomonocytic, monocytic and erythroleukemia) , chronic leukemias (such as chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia) , polycythemia vera, lymphoma, Hodgkin’s disease, non-Hodgkin’s lymphoma (indolent and high grade forms) , multiple myeloma, Waldenstrom’s macroglobulinemia, heavy chain disease, myelodysplastic syndrome, hairy cell leukemia and myelodysp
  • Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas) . Examples of solid tumors, such as sarcomas and carcinomas, comprise fibrosarcoma, myxosarcoma, liposarcoma, mesothelioma, malignant lymphoma, pancreatic cancer and ovarian cancer.
  • the CAR-modified T cells of the invention may also serve as a type of vaccine for ex vivo immunization and/or in vivo therapy in a mammal.
  • the mammal is a human.
  • cells are isolated from a mammal (preferably a human) and genetically modified (i.e., transduced or transfected in vitro) with a vector expressing a CAR disclosed herein.
  • the CAR-modified cell can be administered to a mammalian recipient to provide a therapeutic benefit.
  • the mammalian recipient may be a human and the CAR-modified cell can be autologous with respect to the recipient.
  • the cells can be allogeneic, syngeneic or xenogeneic with respect to the recipient.
  • the present invention also provides compositions and methods for in vivo immunization to elicit an immune response directed against an antigen in a patient.
  • the present invention provides methods for treating tumors comprising administering to a subject in need thereof, a therapeutically effective amount of the CAR-modified T cells of the invention.
  • the CAR-modified T cells of the present invention may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL-2, IL-17 or other cytokines or cell populations.
  • pharmaceutical compositions of the present invention may comprise a target cell population as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
  • compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide) ; and preservatives.
  • buffers such as neutral buffered saline, phosphate buffered saline and the like
  • carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins such as glucose,
  • compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented) .
  • the quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient’s disease, although appropriate dosages may be determined by clinical trials.
  • compositions of the present invention can be administered at a dosage of 10 4 to 10 9 cells/kg body weight, preferably 10 5 to 10 6 cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages.
  • the cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al, New Eng. J. of Med. 319: 1676, 1988) .
  • the optimal dosage and treatment regime for a particular patient can readily be determined by one skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly.
  • compositions described herein may be administered to a patient subcutaneously, intradermaliy, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v. ) injection, or intraperitoneally.
  • the T cell compositions of the present invention are administered to a patient by intradermal or subcutaneous injection.
  • the T cell compositions of the present invention are preferably administered by i.v. injection.
  • the compositions of T cells may be injected directly into a tumor, lymph node, or site of infection.
  • cells activated and expanded using the methods described herein, or other methods known in the art where T cells are expanded to therapeutic levels are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efalizumab treatment for psoriasis patients or other treatments for PML patients.
  • agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efalizumab treatment for psoriasis patients or other treatments for PML patients.
  • the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunotherapeutic agents.
  • the cell compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, or the use of chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT) , cyclophosphamide.
  • chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT) , cyclophosphamide.
  • subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
  • subjects receive an infusion of the expanded immune cells of the present invention.
  • expanded cells are administered before or following surgery.
  • the dosage of the above treatments to be administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment.
  • the scaling of dosages for patient administration can be performed according to art-accepted practices.
  • 1 ⁇ 10 6 to 1 ⁇ 10 10 of the modified T cells of the invention e.g., CAR-T-19/20 cells
  • the extracellular antigen binding domain is specific anti-CD20 scFv and anti-CD19 scFv; the CAR formed by combining the specific anti-CD20 scFv and anti-CD19 scFv to a specific hinge region and an intracellular domain shows a great ability of killing tumor cells with low cytotoxicity and low side effects.
  • the chimeric antigen receptor provided by the invention can achieve stable expression and membrane localization of CAR protein after T cells are infected by lentivirus carrying CAR gene.
  • the CAR-modified T cell of the present invention has a longer survival time in vivo and strong anti-tumor efficacy; the optimized CAR with the IgG4 Hinge-CH2-CH3 linker region can avoid the binding of the Fc receptor and the subsequent ADCC effect (antibody-dependent cytotoxicity) .
  • the bispecific chimeric antigen receptor of the present invention comprises both anti-CD20 scFv and anti-CD19 scFv, and the DNA footprint is significantly reduced (the DNA length is reduced by 40%) , and the size of structure is small, which is beneficial for the packaging and transduction efficiency of viral vectors, thus directly improving clinical efficacy.
  • the bispecific CAR of the invention has lower cost, higher cure rate, and more safety.
  • T-cells modified with TN-LEU-19 or TH-OF-19 chimeric antigen receptors of the present invention have very strong ability to kill in vitro and to clear malignant tumors carrying CD19 and CD20 positive antigens in vivo, and Ofatumumab is stronger. This provides a new effective method and preparation for the clinical application of CAR-T in the treatment of CD19 and CD20-positive leukemias and lymphomas.
  • the CAR-T cells of the present invention have a killing effect on most malignant B-cell tumors, have a wider treatment range and a larger coverage rate, and can more effectively prevent tumor cells from escaping.
  • the full-length DNA was synthesized and cloned to construct the encoding plasmids.
  • the pWPT lentiviral vector was selected as a cloning vector, and the cloning sites were BamH I and Sal I sites.
  • the structures of the two CARs designed in the present invention are shown in Figure 1.
  • the amino acid sequence of TN-LEU-19 is shown in SEQ ID NO: 15, and the amino acid sequence of TN-OF-19 is shown in SEQ ID NO: 16 (with a structure of L- (OF) VL- (OF) VH-I- (FMC63) VH- (FMC63) VL-H-TM-C-CD3 ⁇ ) .
  • PBMCs were isolated from venous blood of healthy donor by density gradient centrifugation. On day 0, PBMCs were activated in a cell culture flask previously coated with CD3 monoclonal antibody (OKT3) and Retronectin (TAKARA) . The medium was GT-551 cell culture medium containing 1%human albumin and 300 U/mL recombinant human interleukin 2 (IL-2) . On day 3, activated PBMCs were transduced with purified TN-LEU-19 or TN-OF-19 lentivirus solution. Starting from day 6, TN-OF-19 and TN-LEU-19 CAR-T cells can be taken for corresponding activity assay. Protein L method was used to determine the expression level of CAR gene-encoded protein on the surface of T cell membrane in CAR-T cells cultured for 7 days.
  • IL-2 human interleukin 2
  • T cell activation marker CD137 and IFN ⁇ release were detected using CD19/20 bi-specific CAR-T cells cultured for 7 days.
  • 1 ⁇ 10 5 of CAR-T cells were co-cultured respectively with CD19, CD20-positive K562-CD19+, K562-CD20+, K562-CD19+CD20+ and Raji (naturally expressing CD19 and CD20) tumor cell line, as well as CD19CD20-negative K562 tumor cell line, or without tumor cells, in 200 ⁇ l of GT-551 medium for 18h with a ratio of 1: 1. Then the expression level of CD137 on the surface of T cell and the secretion level of IFN ⁇ in the culture supernatant were detected respectively.
  • the CAR-T cells prepared in Example 2 were tested for cytotoxicity by LDH release assay.
  • Target cells are K562, K562-CD19+, K562-CD20+, K562-CD19+CD20+, and Raji cells; and effector cells are NT, TN-LEU-19, and TN-OF-19 cells.
  • the results are shown in Figure 3A. Both TN-LEU-19 and TN-OF-19 CAR-T cells can well induce apoptosis and release LDH in CD19/20-positive tumor cells.
  • CD107a (amarker of T-Cell Degranulation) release levels during tumor cell killing induced by CAR-T19/20s cells were analyzed by flow cytometry. 1 ⁇ 10 5 cells of effective cell CAR-T19/20s (TN-OF-19 and TN-LEU-19) were co-cultured respectively with 2 ⁇ 10 5 of target tumor cells.
  • the target cells are K562-CD19+, K562-CD20+, K562-CD19+CD20+, and K562 cells, Raji cells, Romas cells (CD19+CD20+) , respectively.
  • the results are shown in Figure 3B. Both CART cells can well induce the release of CD107a during tumor cell killing.
  • TN-OF-19 cells have a slightly higher release of CD107a as a marker of cytotoxicity than TN-LEU-19 cells.
  • the tumor cells injected in animals were Raji cells carrying a luciferase reporter gene (Raji expressing luciferase) .
  • Raji were injected and grown in mice for one week, and then effector T cells were injected.
  • the effector T cells were divided into three groups: NT, TN-LEU-19, and TN-OF-19.
  • the expanded effector T cells were injected into the NSG mice through the tail vein, and then the fluorescence intensity of the mice (via IVIS fluorescence imaging) and the weight of the mice were recorded every 7 days. The experiment was stopped on the 21st day, and the statistical results were analyzed.
  • Figure 4A shows the weight change of mice after the injection of effector T cells into the three groups of mice. Compared with two types of CART cells CART-TN-OF-19 and CART-TN-LEU-19, the mice of NT showed a significant decrease in body weight and the mice in both CART cell groups gained slightly more weight.
  • Figure 4B shows the average fluorescence intensity of the three groups of mice. The results show that the average fluorescence intensity of the mice in the NT group increased significantly, while the average of the fluorescence intensities of the mice in the two CART cell groups decreased, indicting both TN-OF-19 and TN-LEU-19 CART cells can inhibit the growth of tumor compared with NT.
  • TN-OF-19 cells have better inhibition on tumor growth than TN-LEU-19 cells after day14, and the tumor growth curve of TN-LEU-19 group relapsed significantly.
  • Figure 4C shows the IVIS imaging of fluorescence intensity in two CART cell groups and NT group.
  • TN-OF-19 CAR-T cells can inhibit or kill tumor cells better than TN-LEU-19 cells in vivo.
  • TN-OF-19 (L) , TN-OF-19 (M) , TN-OF-19 (H) groups were treated separately with 1 ⁇ 10 6 , 2.5 ⁇ 10 6 , and 5 ⁇ 10 6 CAR+ T cells via tail vein injection.
  • Figure 5A shows that bi-specific TN- OF-19 CAR-T cells can inhibit or kill tumor cells better than CD19 specific CAR-T cells in vivo. Especially at early stage of treatment, bi-specific TN-OF-19 CAR-T shows significantly faster inhibitory effects.
  • Figure 5B shows the IVIS imaging of fluorescence intensity in 4 CAR-T cell groups and NT group.
  • Example 6 Antigen specificity of the CD20/CD19 bi-specific scFV in TN-OF 19 CAR.
  • a chimeric rabbit monoclonal antibody was generated by linking the CD20 scFv, derived from the Ofatumumab mAb and the CD19 scFv, derived from the FMC63 mAb in frame with a rabbit IgG1 Fc region.
  • CD19 and CD20 scFvs were alternatively linked by a G4S linker.
  • the molecular order is OF VL-VH-G4S-FMC63 VH-VL, which is the same as scFVs in TN-OF-19.
  • the chimeric antibody was expressed in 293T cells after transient transfection.
  • FIG. 6 shows the chimeric antibody bound to cells with CD19 or CD20 or both, but not to cells lacking both antigens, indicating that the bispecific binding domain required only one cognate antigen for binding and no new specific recognition sites were formed
  • Figure 7 shows the structures of sixteen CD20 specific CARs with six different scFVs and different hinge/TM/signaling domains. Full-length DNA was synthesized and cloned to achieve the construction of encoding plasmids, and we tested the anti-tumor activities of these CARs with various CD20 expressing target cells.
  • Figure 8A shows the results of IFN ⁇ release assay to screen CAR-T20.1, CAR-T20.5, CAR-T20.6, CAR-T20.7, CAR-T20.8, CAR-T20.9 and CAR-T20.10, and among these CAR-Ts, only CAR-T20.9 (Leu16) and CAR-T20.10 (Leu16) showed higher positive IFN ⁇ release.
  • Figure 8B shows the results of IFN ⁇ release assay to screen CAR-T20.1, CAR-T20.9, CAR-T20.10, CAR-T20.11, CAR-T20.12, CAR-T20.13, CAR-T20.14, CAR-T20.15 and CAR-T20.16.
  • CAR-T20.10 Leu16
  • CAR-T20.14 OF
  • Figure 8C shows the results of IFN ⁇ release assay to screen CAR-T20.9, CAR-T20.12, CAR-T20.14, CAR-T20.17, CAR-T20.18, and CAR-T20.19.
  • CAR-T20.14 (OF) and CAR-T20.19 (OF) showed higher positive IFN ⁇ release.
  • Figure 9A shows the results of CAR-T20.17 (Leu16 3 rd generation) , CAR-T20.18 (Leu16 2 nd generation) , CAR-T20.19 (OF 2 nd generation) cells tested for cytotoxicity by LDH release assay.
  • Target cells are CD20 positive cell lines Raji and Ramos, and CD20 negative Molt4. Both All three CD20 CAR-T cells can induce apoptosis and release LDH in CD20-positive tumor cells indicating CAR-T20.17, CAR-T20.18, and CAR-T20.19 had strong killing effects on target cells CD20-positive Raji and Romas cells.
  • Figure 9B shows the in vivo inhibition of tumor growth in NSG mouse studies.
  • the tumor cells injected in animals are Raji expressing luciferase.
  • tumor cells Raji were injected and grown in mice for one week, and then effector T cells were injected through the tail vein, and then the fluorescence intensity of the mice (via IVIS fluorescence imaging) and the weight of the mice were recorded every 7 days.
  • the experiment was stopped on the 21st day, and the statistical results were analyzed.
  • the results show that CAR-T20.19 (OF) cells have better inhibition on tumor growth than CAR-T20.17 (Leu16) and CAR-T201.8 (Leu16) cells after day14.
  • Example 7 In summary of Example 7 ( Figure 7-9) , through a large number of experiments and comparison, it was found that 20.1, 20.2, 20.4, 20.5, 20.6, 20.7, 20.8 and 20.15 were basically invalid, and 20.11, 20.12 and 20.13 had certain effects, but the effects of them were less than that of 20.9, 20.10, 20.14, 20.16, 20.17, 20.18 and 20.19, wherein the effects of 20.19 (OF) were the best. Based on the above structures, CD20 scFv (OF) and CD19 scFv (FMC63) were tandemly used in a new bispecific chimeric antigen receptor TN-OF-19 and considered as the best candidate for further analysis.
  • OF scFv
  • FMC63 CD19 scFv
  • C-CAR039 i.e. TN-OF-19 CAR-T cells, NCT04317885
  • C-CAR039 was manufactured and infused as a single intravenous dose after a standard 3-day cyclophosphamide/fludarabine conditioning regimen.
  • C-CAR039 was manufactured in a serum free, semi-automated, and digitally closed system with median vein to vein time of 18 days. The manufacturing success rate was 100%.
  • FIG. 10 shows CAR039 r/rNHL study design and flow chart.
  • the median age of patients dosed was 58.5 years (range: 28–71 years) .
  • the median number of prior lines of therapy was 2 (range: 2-5 prior therapies) .
  • C-CAR039 treatment was well tolerated with no grade 3 or higher CRS and no neurotoxicity events. Reversible grade 1 ⁇ 2 CRS was observed in 9 (82%) of patients. Cytopenias due to the conditioning regimen were common and reversible.
  • the best overall response includes 10 complete responses (CRs) and 2 partial responses (PRs) .
  • FIG 11 shows the summary of C-CAR039 clinical results.
  • Figure 12 shows examples of patient before and post C-CAR039 treatment.
  • FIG 13 shows C-CAR039 proliferation and expansion in patient’s blood. The results showed that C-CAR008 cells expanded effectively after injection.
  • Table 4 The relationships of PK profile (AUC 0 ⁇ 28day , Cmax, Tmax, Tlast) , CAR-T cell dose and clinical responses.
  • C-CAR039 shows promising efficacy and a favorable safety profile in the early clinical trial in patients with r/r NHL.
  • the early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T therapies.
  • C-CAR066 is a novel 2nd generation chimeric antigen receptor T (CAR-T) therapy. Preclinical studies suggest that C-CAR066 (derived from scFVs of Ofatumumab) has superior anti-tumor activity compared to CAR-Ts derived from scFVs of Leu16, Rituximab, and Obinutuzumab,
  • NCT04036019 is a single arm, single-center, non-randomized phase I clinical trial to evaluate the safety and efficacy of C-CAR066 in subjects with r/r B cell lymphoma who were previously treated with anti-CD19 CAR-T therapy.
  • the primary objective of the study is to evaluate incidence and severity of treatment emergent adverse events.
  • the secondary objectives include determining overall response rate (ORR) , PFS, and OS.
  • ORR overall response rate
  • PFS personal filter filtration rate
  • OS overall response rate
  • C-CAR066 is manufactured in a serum free, semi-automated, and digitally closed system.
  • C-CAR066 is administered to patients as a single intravenous dose after a standard 3-day cyclophosphamide/fludarabine conditioning regimen.
  • Figure 14 shows the C-CAR066-NHL study design.
  • Figure 15 shows an example of PET-CT of a patient before and after treated with C-CAR066.
  • C-CAR066 has a favorable safety profile and shows promising early efficacy in patients with r/r NHL following CD19 CAR-T therapy. It shows that C-CAR066 has a different mechanism of action compared to anti-CD-19 CAR-T therapy.
  • CD20 and CD19 tumor antigens might lead to superior clinical benefit to targeting either CD19 or CD20 alone in B-cell malignancy patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/CN2020/109645 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof Ceased WO2021184673A1 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
CA3169235A CA3169235A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
JP2022506548A JP7624967B2 (ja) 2020-03-17 2020-08-17 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
US17/911,502 US20230104705A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
UAA202203670A UA129998C2 (uk) 2020-03-17 2020-08-17 Комбінований химерний антигенний рецептор, що націлює cd19 і cd20, та його застосування
IL296473A IL296473B2 (en) 2020-03-17 2021-03-17 A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
AU2021238330A AU2021238330B2 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting CD19 and CD20 and applications thereof
PCT/US2021/022779 WO2021188681A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
DK21772208.1T DK3989986T3 (da) 2020-03-17 2021-03-17 Kombineret kimær antigenreceptor målrettet mod cd19 og cd20 og anvendelser deraf
JP2022506726A JP7212222B2 (ja) 2020-03-17 2021-03-17 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
IL317912A IL317912A (en) 2020-03-17 2021-03-17 A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
LTEPPCT/US2021/022779T LT3989986T (lt) 2020-03-17 2021-03-17 Suderintas chimerinis antigenų receptorius, skirtas cd19 ir cd20, ir jo taikymas
RS20250825A RS67131B1 (sr) 2020-03-17 2021-03-17 Kombinovani himerni antigenski receptor usmeren na cd19 i cd20 i njegove primene
KR1020237011866A KR20230053705A (ko) 2020-03-17 2021-03-17 Cd19 및 cd20을 표적화하는 조합된 키메라 항원 수용체 및 그의 적용
US17/911,524 US20230212255A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
PT217722081T PT3989986T (pt) 2020-03-17 2021-03-17 Recetor de antigénio quimérico combinado dirigido a cd19 e cd20 e aplicações deste
PE2022002042A PE20231643A1 (es) 2020-03-17 2021-03-17 Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos
MX2022011554A MX2022011554A (es) 2020-03-17 2021-03-17 Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y sus aplicaciones.
CA3169239A CA3169239A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
HRP20251006TT HRP20251006T1 (hr) 2020-03-17 2021-03-17 Kombinirani kimerni antigenski receptor usmjeren na cd19 i cd20 i njegove primjene
PL21772208.1T PL3989986T3 (pl) 2020-03-17 2021-03-17 Połączony chimeryczny receptor antygenowy ukierunkowany na cd19 i cd20 i jego zastosowania
NZ793365A NZ793365A (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
KR1020227035401A KR102520550B1 (ko) 2020-03-17 2021-03-17 Cd19 및 cd20을 표적화하는 조합된 키메라 항원 수용체 및 그의 적용
PH1/2022/552463A PH12022552463A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
EP21772208.1A EP3989986B1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
EP25182520.4A EP4631525A3 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
BR112022018677A BR112022018677A2 (pt) 2020-03-17 2021-03-17 Receptor de antígeno quimérico combinado que alveja cd19 e cd20 e aplicação do mesmo
ES21772208T ES3039539T3 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
FIEP21772208.1T FI3989986T3 (fi) 2020-03-17 2021-03-17 Yhdistetty kimeerinen antigeenireseptori, joka kohdistuu cd19:ään ja cd20:een, ja sen käyttötapoja
CR20220507A CR20220507A (es) 2020-03-17 2021-03-17 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones
SI202130340T SI3989986T1 (sl) 2020-03-17 2021-03-17 Kombinirani kimerski receptorji antigena, usmerjeni v cd19 in cd20, in njihova uporaba
CN202180035520.4A CN115955974A (zh) 2020-03-17 2021-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
SM20250287T SMT202500287T1 (it) 2020-03-17 2021-03-17 Recettore dell'antigene chimerico combinato che mira cd19 e cd20 e applicazioni di esso
CL2022002522A CL2022002522A1 (es) 2020-03-17 2022-09-15 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones.
DO2022000195A DOP2022000195A (es) 2020-03-17 2022-09-20 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones
CONC2022/0014259A CO2022014259A2 (es) 2020-03-17 2022-10-05 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones
JP2022202035A JP7624961B2 (ja) 2020-03-17 2022-12-19 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
AU2023200268A AU2023200268A1 (en) 2020-03-17 2023-01-19 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
JP2025008195A JP2025066770A (ja) 2020-03-17 2025-01-21 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010188038.1A CN113402612A (zh) 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN202010188038.1 2020-03-17
US16/877,069 US11207349B2 (en) 2020-03-17 2020-05-18 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US16/877,069 2020-05-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/877,069 Continuation-In-Part US11207349B2 (en) 2020-03-17 2020-05-18 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/911,524 Continuation-In-Part US20230212255A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof

Publications (1)

Publication Number Publication Date
WO2021184673A1 true WO2021184673A1 (en) 2021-09-23

Family

ID=77677447

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2020/109645 Ceased WO2021184673A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
PCT/US2021/022779 Ceased WO2021188681A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2021/022779 Ceased WO2021188681A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof

Country Status (30)

Country Link
US (5) US11207349B2 (enExample)
EP (2) EP3989986B1 (enExample)
JP (4) JP7624967B2 (enExample)
KR (2) KR102520550B1 (enExample)
CN (2) CN113402612A (enExample)
AU (2) AU2021238330B2 (enExample)
BR (1) BR112022018677A2 (enExample)
CA (2) CA3169235A1 (enExample)
CL (1) CL2022002522A1 (enExample)
CO (1) CO2022014259A2 (enExample)
CR (1) CR20220507A (enExample)
DK (1) DK3989986T3 (enExample)
DO (1) DOP2022000195A (enExample)
EC (1) ECSP22079948A (enExample)
ES (1) ES3039539T3 (enExample)
FI (1) FI3989986T3 (enExample)
HR (1) HRP20251006T1 (enExample)
IL (2) IL296473B2 (enExample)
LT (1) LT3989986T (enExample)
MX (1) MX2022011554A (enExample)
NZ (1) NZ793365A (enExample)
PE (1) PE20231643A1 (enExample)
PH (1) PH12022552463A1 (enExample)
PL (1) PL3989986T3 (enExample)
PT (1) PT3989986T (enExample)
RS (1) RS67131B1 (enExample)
SI (1) SI3989986T1 (enExample)
SM (1) SMT202500287T1 (enExample)
UA (1) UA129998C2 (enExample)
WO (2) WO2021184673A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044743A1 (en) * 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
WO2024206884A1 (en) * 2023-03-31 2024-10-03 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
KR102739632B1 (ko) * 2022-02-09 2024-12-05 한림대학교 산학협력단 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023208157A1 (zh) * 2022-04-29 2023-11-02 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体及其应用
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
CN116514992B (zh) * 2022-11-07 2024-05-24 武汉波睿达生物科技有限公司 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
CN119954967A (zh) * 2023-05-19 2025-05-09 优恺泽生物医药(上海)有限公司 免疫效应细胞及其应用
WO2025021113A1 (zh) * 2023-07-25 2025-01-30 上海药明巨诺生物医药研发有限公司 用于治疗与cd20相关的疾病的融合蛋白
WO2025030693A1 (zh) * 2023-08-08 2025-02-13 星尘生物科技(上海)有限公司 双特异性嵌合抗原受体及其应用
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
CN108017717A (zh) * 2018-01-24 2018-05-11 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
CN109536455A (zh) * 2018-12-11 2019-03-29 武汉波睿达生物科技有限公司 一种car-nk细胞及其制备方法和应用
CN109575143A (zh) * 2018-12-29 2019-04-05 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用
WO2019128952A1 (zh) * 2017-12-26 2019-07-04 沣潮医药科技（上海）有限公司 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6074841A (en) 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
KR20120125634A (ko) 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
CN101544694A (zh) 2008-03-28 2009-09-30 上海中信国健药业有限公司 抗cd20四价抗体、其制备方法和应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
EP2872170A4 (en) 2012-07-13 2016-06-22 Zymeworks Inc ASYMMETRIC BISPECIFIC HETERODIMERS WITH ANTI-CD3 CONSTRUCTS
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2015092865A (ja) 2013-11-13 2015-05-18 国立大学法人名古屋大学 ヒト化抗ｃｄ２０キメラ抗原レセプター
MX386422B (es) * 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
ES2767423T3 (es) 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3149044B1 (en) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting cd-19
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
KR102804498B1 (ko) 2014-12-03 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 방법 및 조성물
SI3240805T1 (sl) * 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
WO2016097231A2 (en) 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
WO2016110576A1 (en) 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
US11248058B2 (en) 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
GB201506223D0 (en) 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
WO2016168773A2 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN108603170A (zh) 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
SG10201912734PA (en) 2015-08-05 2020-02-27 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108135932A (zh) 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
CN108602872A (zh) 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
MA44314A (fr) * 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
MX2018010415A (es) 2016-03-18 2018-11-29 Hutchinson Fred Cancer Res Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CA3018253A1 (en) * 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
CN107868791B (zh) * 2016-09-26 2021-11-23 阿思科力(苏州)生物科技有限公司 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用
AU2017341047B2 (en) * 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN107936120B (zh) * 2016-10-13 2021-03-09 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN108250301A (zh) 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
CN108276493B (zh) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
AU2018225153A1 (en) * 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
KR20190133017A (ko) 2017-03-27 2019-11-29 에프. 호프만-라 로슈 아게 개선된 항원 결합 수용체 구성
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US11434290B2 (en) 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
CN109423495A (zh) 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 一种双靶向嵌合抗原受体及其用途
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
US11905528B2 (en) 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
US20220218745A1 (en) 2017-12-22 2022-07-14 2Seventy Bio, Inc. Multivalent chimeric antigen receptor
CN109971725B (zh) 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN108285486A (zh) 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
US20230183313A1 (en) 2018-02-11 2023-06-15 Jiangsu Hengrui Medicine Co., Ltd. Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
CN108715616A (zh) * 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 靶向人源化间皮素的嵌合抗原受体方法和用途
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
KR20210033941A (ko) 2018-04-28 2021-03-29 이뮤노테크 바이오팜 씨오., 엘티디. 개선된 t-세포 요법
CN110526983B (zh) 2018-05-24 2022-02-11 北京马力喏生物科技有限公司 改良型抗cd19 car-t细胞
WO2019232444A1 (en) 2018-05-31 2019-12-05 Washington University Chimeric antigen receptor t cells (car-t) for the treatment of cancer
CN110606893B (zh) 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020033273A1 (en) 2018-08-04 2020-02-13 AbCyte Therapeutics Inc. Multi-function and multi-targeting car system and methods for use thereof
JP2022501067A (ja) 2018-09-26 2022-01-06 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
CN113412117B (zh) * 2018-12-12 2025-03-04 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CN113330038A (zh) 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
JP7395200B2 (ja) 2019-03-25 2023-12-11 イミュンワーク インク． 金属結合モチーフを有する複合ポリペプチド及びそれを備える分子構築物
CN112390891B (zh) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
CN110845623B (zh) * 2019-10-11 2021-07-09 厦门大学 一种egfr特异性嵌合抗原受体及其应用
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN112608387B (zh) 2020-12-21 2023-05-05 汤朝阳 Cd19和cd20双靶点嵌合抗原受体及其应用
US20240115605A1 (en) 2021-01-27 2024-04-11 Cellular Biomedicine Group, Inc. Chimeric antigen receptors targeting cd20

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
WO2019128952A1 (zh) * 2017-12-26 2019-07-04 沣潮医药科技（上海）有限公司 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用
CN108017717A (zh) * 2018-01-24 2018-05-11 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
CN109536455A (zh) * 2018-12-11 2019-03-29 武汉波睿达生物科技有限公司 一种car-nk细胞及其制备方法和应用
CN109575143A (zh) * 2018-12-29 2019-04-05 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHU, F. ET AL.: "Closed-system manufacturing of CD 19 and dual-targeted CD 20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center", CYTOTHERAPY, vol. 20, 31 December 2018 (2018-12-31), pages 394 - 406, XP055518886, DOI: 10.1016/j.jcyt.2017.09.005 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044743A1 (en) * 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
WO2024206884A1 (en) * 2023-03-31 2024-10-03 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
US12311022B2 (en) 2023-03-31 2025-05-27 AbelZeta Inc. Bispecific chimeric antigen receptors targeting CD20 and BCMA
US12458667B2 (en) 2023-03-31 2025-11-04 AbelZeta Inc. Bispecific chimeric antigen receptors targeting CD20 and BCMA

Also Published As

Publication number Publication date
ECSP22079948A (es) 2022-12-30
IL296473B1 (en) 2025-01-01
UA129998C2 (uk) 2025-10-08
PT3989986T (pt) 2025-09-08
JP2022536195A (ja) 2022-08-12
PL3989986T3 (pl) 2025-09-29
IL317912A (en) 2025-02-01
KR20230053705A (ko) 2023-04-21
EP3989986B1 (en) 2025-07-09
JP2025066770A (ja) 2025-04-23
SI3989986T1 (sl) 2025-10-30
AU2023200268A1 (en) 2023-02-16
CN115955974A (zh) 2023-04-11
CL2022002522A1 (es) 2023-04-21
LT3989986T (lt) 2025-09-10
IL296473B2 (en) 2025-05-01
DOP2022000195A (es) 2023-02-28
DK3989986T3 (da) 2025-08-18
HRP20251006T1 (hr) 2025-11-07
JP2023027314A (ja) 2023-03-01
US20220031752A1 (en) 2022-02-03
US20210290673A1 (en) 2021-09-23
PE20231643A1 (es) 2023-10-16
US11633430B2 (en) 2023-04-25
KR20220145411A (ko) 2022-10-28
FI3989986T3 (fi) 2025-08-15
EP4631525A2 (en) 2025-10-15
MX2022011554A (es) 2022-12-13
JP7624967B2 (ja) 2025-01-31
US11207349B2 (en) 2021-12-28
ES3039539T3 (en) 2025-10-22
WO2021188681A1 (en) 2021-09-23
CA3169235A1 (en) 2021-09-23
KR102520550B1 (ko) 2023-04-12
BR112022018677A2 (pt) 2023-02-23
SMT202500287T1 (it) 2025-11-10
PH12022552463A1 (en) 2024-01-03
NZ793365A (en) 2023-03-31
CR20220507A (es) 2022-11-22
AU2021238330B2 (en) 2023-02-23
US20220249568A1 (en) 2022-08-11
US11439665B2 (en) 2022-09-13
US12448432B2 (en) 2025-10-21
US20220288123A1 (en) 2022-09-15
CN113402612A (zh) 2021-09-17
EP4631525A3 (en) 2025-12-24
RS67131B1 (sr) 2025-09-30
JP7624961B2 (ja) 2025-01-31
JP2023518134A (ja) 2023-04-28
US20240139243A1 (en) 2024-05-02
IL296473A (en) 2022-11-01
AU2021238330A1 (en) 2022-11-17
CO2022014259A2 (es) 2022-10-31
JP7212222B2 (ja) 2023-01-25
EP3989986A4 (en) 2022-10-12
EP3989986A1 (en) 2022-05-04
CA3169239A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US11633430B2 (en) Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US20240327533A1 (en) Engineered immune cells targeting bcma and their uses thereof
US20230053305A1 (en) BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application Thereof
US20230104705A1 (en) Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
US20230212255A1 (en) Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
WO2020224605A1 (zh) 靶向bcma的工程化免疫细胞及其用途
WO2022164886A2 (en) Chimeric antigen receptors targeting cd20
US20240000839A1 (en) Bcma-targeted chimeric antigen receptors
AU2023204159B2 (en) Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
NZ796581A (en) Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
CN119350497A (zh) 人源化抗cd19单链可变区片段及其用途
EA050505B1 (ru) Комбинированный химерный антигенный рецептор, нацеленный на cd19 и cd20, и его применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20925464

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022506548

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3169235

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20925464

Country of ref document: EP

Kind code of ref document: A1